DIABETES CARE

Teplizumab: new emerging modalities in Type 1 Diabetes

July 8, 2024 Dr. Smita Ramachandran 2 min read
Teplizumab : new emerging modalities in Type 1 Diabetes

Type 1 Diabetes Mellitus (T1DM) is an autoimmune condition characterized by immune-mediated destruction of pancreatic beta cells, culminating in lifelong dependence on daily insulin. In recent years, groundbreaking disease-modifying therapies like Teplizumab have emerged, representing the first approved immunotherapy to delay the clinical onset of T1DM.

Key Clinical Takeaway: In pivotal clinical trials, a single 14-day infusion course of Teplizumab successfully delayed the clinical onset of Stage 3 Type 1 Diabetes by a median of 24 months in high-risk pediatric and young adult patients.
Q1

What is Teplizumab and How Does it Work?

Teplizumab is a humanized monoclonal antibody targeting the CD3 antigen on autoreactive T-lymphocytes. By deactivating destructive killer T-cells and supporting regulatory T-cells, Teplizumab preserves functional insulin-producing pancreatic beta-cell mass before clinical symptoms begin.

Q2

What Are the Recognized Stages of Type 1 Diabetes?

Understanding the preclinical progression of Type 1 Diabetes is essential for identifying therapy candidates:

Stage 1

Asymptomatic Autoimmunity

Presence of ≥2 islet autoantibodies with completely normal blood glucose and normal glucose tolerance.

Stage 2

Presymptomatic Dysglycemia

Presence of ≥2 autoantibodies with impaired fasting glucose or abnormal oral glucose tolerance (OGTT).

Stage 3

Clinical Symptomatic T1D

Manifestation of hallmark symptoms (polyuria, polydipsia, weight loss) requiring daily exogenous insulin therapy.

Stage 4

Established Longstanding T1D

Complete or near-complete pancreatic beta cell exhaustion requiring intensive lifelong insulin delivery.

Q3

Who is Eligible for Teplizumab Therapy?

Regulatory approval focuses specifically on Stage 2 Type 1 Diabetes in patients aged 8 years and older who meet both of the following criteria:

  • Demonstrated presence of at least two positive diabetes autoantibodies (such as GAD65, IA-2, ZnT8, or IAA).
  • Demonstrated dysglycemia on oral glucose tolerance testing without yet entering diabetic ketoacidosis or requiring daily insulin.
Q4

How is the Medication Administered?

Teplizumab is administered as a continuous once-daily intravenous infusion for 14 consecutive days under controlled clinical observation. Daily dosing is incrementally titrated over the first 5 days to mitigate infusion reactions and cytokine release.

Q5

What Are Potential Side Effects and Monitoring Requirements?

The most common clinical adverse reactions observed during the 14-day infusion include:

  • Transient lymphopenia (temporary reduction in circulating white blood cells)
  • Mild cytokine release syndrome (manifesting as fever, headache, nausea, and chills)
  • Self-limiting skin rash and transaminase elevations

The advent of disease-modifying immunotherapy highlights the immense power of early screening in high-risk pediatric populations to preserve insulin function and delay diabetes onset.

Have questions about your child's health?

Consult our specialist for personalised guidance and care.

Book an Appointment